Category: Prostate Cancer Detection

Cancer stayed in the headlines all through 2025, and one thread ran through nearly every story: timing. Some cancers announce themselves early. Others stay silent until the options narrow. For prostate cancer, an annual PSA test starting in midlife is what separates the two, and today's imaging has removed the old objections to getting tested. keep reading

Roughly one million prostate biopsies happen in the U.S. each year because of a high PSA result, and about 75 percent of them find no cancer at all. That is hundreds of thousands of needles for nothing. Multiparametric MRI with PI-RADS scoring, paired with PSA density, adds an accurate step in between that separates real cancer from a false alarm. keep reading

Combining multiparametric MRI with genomic testing is revolutionizing prostate cancer detection and treatment. By leveraging the strengths of both technologies, doctors can achieve more accurate diagnoses, guide personalized treatment decisions, and improve patient outcomes. Learn how these tools are shaping the future of prostate cancer care. keep reading

Here's an uncomfortable truth: most elevated PSA tests turn out to be false alarms, yet they still steer hundreds of thousands of men toward a needle biopsy every year. A smarter path exists. By adding the Stockholm3 blood test and an MRI before anyone reaches for a needle, doctors can tell which men genuinely need a biopsy and which can safely wait, sparing a lot of worry and harm. keep reading

What if the biopsy you were told was MRI-guided wasn't really MRI-guided at all? Fusion technology merges an earlier MRI scan with real-time ultrasound, and the handoff is imperfect. New research adds a fresh concern: as prostate volume grows, detection of clinically significant cancer drops, no matter how carefully the target was chosen. keep reading

For decades, the gloved-finger exam was a standard part of every man's annual physical. Now the evidence is catching up with what many doctors suspected: the digital rectal exam misses too much and finds too little. With MRI able to view the entire prostate, major guidelines have quietly pushed the old exam to the bottom of the list. keep reading

Skip the contrast agent, and a prostate MRI gets faster and cheaper, but it loses the one signal that makes cancer impossible to miss: abnormal blood flow. That trade-off is why the third MRI sequence matters, and why a newly approved low-dose contrast agent is worth watching. It offers the same vascular proof with a fraction of the gadolinium. keep reading

Prostate cancer has a reputation as an older man's diagnosis, yet a growing number of men in their 20s, 30s, and 40s are hearing it too. Inherited gene mutations, missed early symptoms, and lifestyle factors all feed the trend, and younger patients often face later-stage disease. Early PSA testing paired with MRI offers a powerful way to catch trouble sooner. keep reading

As many as 75% of PSA tests come back falsely positive, and for years that single number sent men straight to a needle biopsy with all its risks. Today, noninvasive biomarker tests in blood and urine, paired with mpMRI, are reshaping who truly needs the procedure and who can safely be spared the discomfort and the worry. keep reading

A prostate MRI can detect cancer without contrast but how confident can a doctor be? DCE-MRI adds a third layer of information by capturing tumor blood flow patterns that plain MRI can't show. Gadolinium makes this possible, and modern formulations have an impressive safety record: over 170 million doses studied. keep reading